In 2023, antiinfective medicine sales in Switzerland stood at $62.8 per capita. The forecasted data indicates a consistent year-on-year increase in sales from 2024 to 2028. Specifically, we expect growth rates of 0.6% in 2024, 0.6% in 2025, 0.6% in 2026, 0.5% in 2027, and 0.6% in 2028. The compound annual growth rate (CAGR) over the forecasted five-year period is 0.58% annually.
Future trends to watch for include advancements in antiinfective treatments, potential impacts of public health policies, and emerging resistances to current medications. Innovation in healthcare and biotechnologies could also play a critical role in shaping the market dynamics for antiinfective medicines in the coming years.
